WATERTOWN, Mass. — September 15, 2026
Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KST-6051, an oral pan-KRAS inhibitor being developed for patients with advanced or metastatic solid tumors harboring KRAS mutations. The designation represents an important regulatory milestone as Kestrel advances its lead program through clinical development. The FDA Fast Track program is intended to facilitate development and review of therapies addressing serious conditions and unmet medical needs, providing opportunities for more frequent FDA interactions and written communications during development. Eligible programs may also qualify for mechanisms such as Priority Review, Accelerated Approval and rolling submission of a marketing application when applicable criteria are met. Kestrel said the designation will support closer engagement with the FDA as KST-6051 advances through its ongoing Phase 1 program.
KST-6051 Enters Clinical Evaluation in FALCON Study
KST-6051 is being evaluated in the first-in-human Phase 1 FALCON study (NCT07458347) in patients with advanced or metastatic KRAS-mutant solid tumors. The dose-escalation study is designed to evaluate the investigational therapy as Kestrel begins establishing its clinical profile in a patient population with significant unmet treatment needs. KST-6051 is designed as a potent and selective oral pan-KRAS inhibitor with activity against KRAS in both its active GTP-bound and inactive GDP-bound states. According to preclinical findings reported by the company, the candidate demonstrated on-target pathway modulation, anti-proliferative activity and anti-tumor efficacy at well-tolerated doses across multiple human KRAS-mutant tumor models. The clinical program is intended to determine appropriate dosing and further characterize safety, pharmacokinetics and preliminary anti-tumor activity as KST-6051 moves toward broader development.
Pan-KRAS Approach Targets Multiple Solid Tumors
Kestrel is developing KST-6051 to address a broad spectrum of KRAS-driven cancers, rather than limiting the program to a single mutation or tumor type. The company’s planned clinical development strategy includes pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and other malignancies driven by mutated KRAS. KRAS mutations are estimated by the company to occur in approximately 30% of all malignancies, making the pathway a major target for oncology drug development. KST-6051’s activity across both KRAS-GTP and KRAS-GDP states is intended to provide broad pathway coverage while maintaining selectivity for KRAS. The ongoing FALCON study will provide the clinical evidence needed to determine how the preclinical profile translates into patients and whether the candidate can support development across multiple KRAS-mutant tumor populations.
Advertisement
Kestrel Builds KRAS Platform With Strategic Partnership
The Fast Track designation strengthens Kestrel Therapeutics’ broader strategy of developing next-generation small-molecule therapies against oncogenic KRAS drivers. The privately held biotechnology company is backed by life-science investors including Pfizer Ventures and Santé Ventures and has entered into a strategic agreement granting AbbVie an exclusive option to acquire Kestrel based on defined development milestones. Kestrel’s team brings experience in oncology drug discovery and development as the company advances KST-6051 through clinical testing. The regulatory designation could facilitate continued interaction with the FDA as clinical data accumulate, although Fast Track status does not guarantee approval or a particular regulatory pathway. With KST-6051 now carrying FDA Fast Track designation and undergoing Phase 1 evaluation, Kestrel is positioning its lead pan-KRAS program for development across multiple KRAS-mutant solid tumors.
Source:Kestrel Therapeutics, press release
